Opportunity Information: Apply for RFA AI 15 054
Apply for RFA AI 15 054
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856,.
- This funding opportunity was created on Oct 21, 2015 and posted on Oct 21, 2015.
- Applicants must submit their applications by Feb 10, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)" (Funding Opportunity Number: RFA AI 15 054) is a discretionary NIH grant program administered under HHS-NIH (listed as HHS-NIH11). It is designed to push promising ideas past the purely exploratory stage and into early translational development, specifically targeting new therapeutic approaches for infections caused by select eukaryotic pathogens. In plain terms, this funding is meant for projects that are not just studying these organisms in the abstract, but are actively working toward identifying and advancing potential treatment candidates, with an emphasis on novelty and a development-oriented plan.
The scientific focus is on early stage translational research that supports the discovery and development of novel therapeutics against eukaryotic pathogens. Eukaryotic pathogens generally include disease-causing organisms such as protozoa, helminths, and pathogenic fungi, which differ biologically from bacteria and viruses and often require different therapeutic strategies. The intent of the FOA, as described, is to encourage work that moves along a pipeline from identifying potential therapeutic leads toward the kinds of data and proof-of-concept evidence that can justify more substantial downstream development. While the provided text does not list specific pathogens or technical scope details, the framing makes it clear the agency is looking for projects that connect discovery to development rather than stopping at basic research findings.
This opportunity uses the NIH R21/R33 funding mechanism, which commonly supports a phased approach. The R21 phase is typically used for exploratory, high-impact early work that reduces scientific risk and demonstrates feasibility, while the R33 phase is generally intended to support the next step of development once predefined milestones are met. In practice, this structure is meant to help applicants propose a project plan that starts with an earlier set of decisive experiments and, if successful, transitions into more advanced development activities without requiring an entirely separate new award at the midpoint. The FOA description highlights "early stage translational research," which aligns with this phased design: generate actionable data early, then build toward a more developed therapeutic concept.
The award is categorized as a grant under the Health funding activity category and is associated with CFDA numbers 93.855 and 93.856. The listed award ceiling is $200,000, which suggests an upper limit on the amount that can be requested or awarded under the terms of this announcement (the source data does not specify whether this ceiling applies per year, per phase, or total, so applicants would normally verify those details in the full FOA text). The source data does not provide the expected number of awards, leaving that field blank, which typically means the exact number was not specified in the summarized record or could vary based on application volume and available funds.
Eligibility is broad and includes a wide range of organizations. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education when specified); for-profit organizations other than small businesses; and small businesses. The listing also includes "Others" with a note to see additional eligibility information in the full announcement, indicating there may be clarifications, constraints, or additional allowable applicant types described in the complete FOA.
Key administrative dates in the record show the opportunity was created and posted on October 21, 2015, with both the original and current closing date listed as February 10, 2016. That means this particular solicitation was time-bound with a single stated deadline in the summary. The opportunity category is listed as discretionary, meaning awards are made based on competitive review and program priorities rather than entitlement or formula distribution.
Overall, the core purpose of this FOA is to stimulate and support projects that are positioned to translate scientific insights into tangible therapeutic candidates or strategies aimed at difficult and often neglected eukaryotic infectious diseases. The use of an R21/R33 structure signals an interest in milestone-driven progress, where early feasibility and proof-of-concept work can transition into a more development-focused phase, all within a single, coherently planned program of research.
FAQs: Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33) (RFA AI 15 054)
What is the title of this grant opportunity?
The opportunity is titled "Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA AI 15 054.
Which agency runs this program?
This is a discretionary NIH grant program administered under HHS-NIH (listed as HHS-NIH11).
What is the main purpose of this funding opportunity?
The purpose is to push promising ideas beyond a purely exploratory stage into early translational development, specifically for new therapeutic approaches targeting infections caused by select eukaryotic pathogens.
What kind of research is this funding meant to support?
It supports early stage translational research focused on the discovery and development of novel therapeutics against eukaryotic pathogens, with an emphasis on novelty and development-oriented planning.
What does "early stage translational research" mean in the context provided?
Based on the description, it means work that moves along a discovery-to-development pipeline, starting with identifying potential therapeutic leads and advancing toward actionable data and proof-of-concept evidence that could justify more substantial downstream development.
Which types of pathogens are in scope?
The scientific focus is on eukaryotic pathogens. The summary describes eukaryotic pathogens as disease-causing organisms such as protozoa, helminths, and pathogenic fungi.
Are specific pathogens listed in the provided information?
No. The provided text does not list specific pathogens or detailed technical scope, but it emphasizes therapeutics for infections caused by select eukaryotic pathogens.
Is this opportunity intended for basic research?
The framing indicates it is not meant for projects that stop at basic research findings. It is intended for projects actively working toward identifying and advancing potential treatment candidates or strategies.
What funding mechanism does this opportunity use?
This opportunity uses the NIH R21/R33 funding mechanism.
How does the R21/R33 phased structure work (as described in the summary)?
The R21 phase is typically used for exploratory, high-impact early work to reduce scientific risk and demonstrate feasibility. The R33 phase is generally intended to support the next step of development once predefined milestones are met.
Why use an R21/R33 mechanism instead of a single-phase award?
The summary indicates the phased structure is intended to let applicants propose a plan that begins with decisive early experiments and, if successful, transitions into more advanced development activities without requiring an entirely separate new award at the midpoint.
Is milestone-driven progress emphasized?
Yes. The description highlights a milestone-driven approach where early feasibility and proof-of-concept work can transition into a more development-focused phase within one coherent program of research.
What is the award ceiling?
The listed award ceiling is $200,000.
Does the summary clarify whether the $200,000 ceiling is per year, per phase, or total?
No. The source data does not specify whether the ceiling applies per year, per phase, or in total.
Is the number of expected awards provided?
No. The expected number of awards field is blank in the summarized record, which typically indicates it was not specified in that summary or could vary based on application volume and available funds.
What is the funding activity category?
The award is categorized under the Health funding activity category.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.855 and 93.856.
Who is eligible to apply?
Eligibility is broad and includes: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education when specified); for-profit organizations other than small businesses; and small businesses.
Does the eligibility list include any "other" categories?
Yes. The listing includes "Others" with a note to see additional eligibility information in the full announcement, which suggests there may be clarifications or additional allowable applicant types in the complete FOA.
Is this grant discretionary or formula-based?
It is listed as discretionary, meaning awards are made based on competitive review and program priorities rather than entitlement or formula distribution.
When was the opportunity created and posted?
The record shows it was created and posted on October 21, 2015.
What was the application closing date listed in the summary?
Both the original and current closing date are listed as February 10, 2016.
Does the summary indicate multiple deadlines or cycles?
No. In the provided summary, it appears to be time-bound with a single stated deadline.
What kinds of projects seem most aligned with the intent of this FOA?
Projects that connect discovery to development: identifying therapeutic leads, generating feasibility and proof-of-concept data, and advancing toward an early therapeutic candidate or strategy for eukaryotic infectious diseases, rather than stopping at descriptive or purely exploratory studies.
What is the overall goal of the FOA in plain terms?
To stimulate and support projects positioned to translate scientific insights into tangible therapeutic candidates or strategies for difficult and often neglected eukaryotic infectious diseases, using a phased R21/R33 approach to support milestone-driven progress.
Browse more opportunities from the same category: Health
Next opportunity: Genomic Data Analysis Network: Specialized Genomic Data Center (U24)
Previous opportunity: Systems Biology Approaches in HIV/AIDS and Substance Use (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 15 054
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 15 054) also looked into and applied for these:
| Funding Opportunity |
|---|
| Supporting the Implementation and Expansion of High Quality, Sustainable and Comprehensive HIV Prevention, Care and Treatment Programs in Faith-Based Organization Facilities in the Republic of Kenya under the President’s Emergency Plan for AIDS Rel Apply for CDC RFA GH16 1620 Funding Number: CDC RFA GH16 1620 Agency: HHS-CDC-CGH Category: Health Funding Amount: $23,000,000 |
| Defeat Malaria Apply for RFI 482 16 000001 Funding Number: RFI 482 16 000001 Agency: USAID-GHA Category: Health Funding Amount: $32,000,000 |
| ATSDR’s Program to Promote Localized Efforts to Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 140303CONT16 Funding Number: CDC RFA TS14 140303CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Research on the Epidemiology, Prevention, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa Apply for RFA IP 16 003 Funding Number: RFA IP 16 003 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $5,000,000 |
| SUPPORTING THE GHANA HEALTH SERVICE (GHS) IN THE STRENGTHENING OF NATIONAL HEALTH MANAGEMENT SYSTEMS IN THE AREAS OF STRATEGIC INFORMATION SYSTEMS, BLOOD SAFETY, AND LABORATORY CAPACITY BUILDING UNDER THE PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS10 10440501SUPP16 Funding Number: CDC RFA PS10 10440501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,500,000 |
| Building Capacity for Human Resources for Health in HIV/AIDS in the Republic of Kenya under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1624 Funding Number: CDC RFA GH16 1624 Agency: HHS-CDC-CGH Category: Health Funding Amount: $3,200,000 |
| Improving the Capacity of University Based Medical Education and Superior Training Institutions to Provide High Quality Education in the Republic of Mozambique Under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1159SUPP Funding Number: CDC RFA GH11 1159SUPP Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Foundational Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT1) Apply for RFA RM 15 019 Funding Number: RFA RM 15 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1158SUPP Funding Number: CDC RFA GH11 1158SUPP Agency: HHS-CDC Category: Health Funding Amount: $5,251,408 |
| NEI Clinical Study Planning Grant Program (R34) Apply for PA 16 038 Funding Number: PA 16 038 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44) Apply for RFA HG 15 039 Funding Number: RFA HG 15 039 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Applied Research Toward Zero Suicide Healthcare Systems (R01) Apply for RFA MH 16 800 Funding Number: RFA MH 16 800 Agency: HHS-NIH11 Category: Health Funding Amount: $600,000 |
| Comprehensive Community-Based HIV Prevention, Linkage, and Retention Services for Key Populations and Adolescent Girls and Young Women in the United Republic of Tanzania under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1652 Funding Number: CDC RFA GH16 1652 Agency: HHS-CDC-CGH Category: Health Funding Amount: $630,000 |
| NHLBI Early Investigator Award (EIA) (R35) Apply for RFA HL 16 025 Funding Number: RFA HL 16 025 Agency: HHS-NIH11 Category: Health Funding Amount: $600,000 |
| Supporting Implementation of HIV and TB Services for Epidemic Control in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1632 Funding Number: CDC RFA GH16 1632 Agency: HHS-CDC-CGH Category: Health Funding Amount: $80,000,000 |
| Enhancing the Government of India’s Capacity to Scale Up and Improve Comprehensive HIV Service Package Quality for People Who Inject Drugs under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH15 154202CONT16 Funding Number: CDC RFA GH15 154202CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Flex Rural Veterans Health Access Program Apply for HRSA 16 015 Funding Number: HRSA 16 015 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Targeted Capacity Expansion-Peer-to-Peer (Short Title: TCE-PTP) Apply for TI 16 008 Funding Number: TI 16 008 Agency: HHS-SAMHS Category: Health Funding Amount: $250,000 |
| Implementing Comprehensive Community Based HIV/AIDS Prevention, Care and Treatment Services in Priority Areas in the Republic of Zambia under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1668 Funding Number: CDC RFA GH16 1668 Agency: HHS-CDC-CGH Category: Health Funding Amount: $2,500,000 |
| Cooperative Agreements for Adolescent and Transitional Aged Youth Treatment Implementation [Youth Treatment – Implementation (Short Title –YT-I)] Apply for TI 16 006 Funding Number: TI 16 006 Agency: HHS-SAMHS Category: Health Funding Amount: $800,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 15 054", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.